6533b837fe1ef96bd12a1f24

RESEARCH PRODUCT

Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

Livio BlasiChiara AnconaMarta CastigliaFrancesco PassigliaMassimiliano AlùAntonio RussoAngela ListìSergio RizzoEmmanuela MussoAlessandro Perez

subject

0301 basic medicinebusiness.industrymedicine.medical_treatment02 engineering and technologyHematologyImmunotherapyctDNA biomarker NSCLC Nivolumab immunotherapy021001 nanoscience & nanotechnology03 medical and health sciences030104 developmental biologyOncologyCirculating tumor DNACancer researchMedicineBiomarker (medicine)Nivolumab0210 nano-technologybusinessPredictive biomarker

description

Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients

yearjournalcountryeditionlanguage
2017-04-01
10.1093/annonc/mdx089http://hdl.handle.net/10447/245238